New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs PE-22-28

Ovagen vs PE-22-28

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
Cognitive Enhancement
PE-22-28
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
Half-Life
Short (minutes); sustained gene-regulatory effects
Relatively short; CNS effects may persist due to neurogenic mechanisms
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
200–400 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
Stacks With